A.R.T. Advisors’s Sage Therapeutics SAGE Stock Holding History

A.R.T. Advisors’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-46,172	Closed	-$3.33M	–	809
2019 Q4	$3.33M	Buy	46,172 +36,601	+382%	+$4.5M	0.16%	148
2019 Q3	$1.34M	Buy	+9,571	New	+$1.6M	0.07%	417
2018 Q4	–	Sell	-13,171	Closed	-$1.86M	–	1603
2018 Q3	$1.86M	Sell	13,171 -2,500	-16%	-$386K	0.08%	321
2018 Q2	$2.45M	Buy	+15,671	New	+$2.46M	0.1%	299
2017 Q4	–	Sell	-33,800	Closed	-$2.1M	–	1629
2017 Q3	$2.1M	Buy	+33,800	New	+$2.65M	0.11%	264
2015 Q3	–	Sell	-27,009	Closed	-$1.97M	–	1556
2015 Q2	$1.97M	Buy	+27,009	New	+$1.74M	0.07%	452
2015 Q1	–	Sell	-17,089	Closed	-$625K	–	1648
2014 Q4	$625K	Buy	+17,089	New	+$637K	0.02%	835

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

A.R.T. Advisors's SAGE Position: Q1 2020 in Review

A.R.T. Advisors sold out of Sage Therapeutics (SAGE) in Q1 2020, closing a stake of 46,172 shares — an estimated $3.33M sold.

A.R.T. Advisors first reported a position in SAGE in Q4 2014 and held it in 7 quarters. The position peaked at $3.33M in Q4 2019. 230 funds tracked by Wall St. Rank hold SAGE as of Q1 2020.

A.R.T. Advisors reported no remaining Sage Therapeutics position as of Q1 2020 after selling out during the quarter.
A.R.T. Advisors sold 46,172 Sage Therapeutics shares in Q1 2020, an estimated $3.33M.
A.R.T. Advisors first reported a position in Sage Therapeutics in Q4 2014 and held it in 7 quarters.
A.R.T. Advisors's Sage Therapeutics position peaked at $3.33M in Q4 2019.
230 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2020.

Based on A.R.T. Advisors's 13F filing for Q1 2020, filed 15 May 2020.